Get started
Author

Anna Nowak

Observed names: Anna K Nowak, Anna K. Nowak
ORCID: 0000-0001-9233-7281
Observed ORCID: 0000-0001-9233-7281
OpenAlex ID: A5045616740
Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2023 · Apostolia M. Tsimberidou, Kerstin Guenther, et al. · Cancer Immunology Research · 14
PDF
Abstract CT007: Phase 2-3 trial of pegargiminase plus chemotherapy versus placebo plus chemotherapy in patients with non-epithelioid pleural mesothelioma
2023 · Peter W. Szlosarek, Ben Creelan, et al. · Cancer Research · 8
Comparative analysis of malignant pleural effusion and peripheral blood reveals unique T cell signatures associated with survival in mesothelioma patients
2025 · Nicola Principe, Kofi L P Stevens, et al. · Oxford Open Immunology · 1
Supplemental Figure 10 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2024 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
Supplemental Figure 3 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2024 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
Supplemental Figure 2 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2024 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
Supplemental Figure 4 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2024 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
Supplemental Figure 4 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2024 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
Supplemental Figure 5 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2024 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
Supplemental Figure 3 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2024 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
Supplemental Figure 2 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2024 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
Supplemental Figure 8 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2024 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
Supplemental Figure 1 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2024 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
Supplemental Figure 10 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2024 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
Supplemental Figure 9 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2024 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
Supplemental Figure 5 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2024 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
Supplemental Figure 6 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2024 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
Supplemental Figure 1 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2024 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
Supplemental Figure 8 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2024 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
Supplemental Figure 7 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2024 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
Supplemental Figure 6 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2024 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
Supplemental Figure 9 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2024 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
Supplemental Figure 7 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2024 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
Supplementary Figure 11 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2024 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
Supplementary Figure 11 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2024 · Apostolia M. Tsimberidou, Kerstin Guenther, et al.
Works count: 84
Citation count: 23
H-index: 2
I10-index: 1
Year
Topic
Type